background
sorafenib
multikinas
inhibitor
approv
treatment
advanc
renal
cell
carcinoma
malign
shown
modul
dendrit
cell
studi
design
examin
effect
sorafenib
macrophag
major
ontogeni
innat
immun
materi
method
macrophag
deriv
sort
monocyt
human
peripher
blood
mononuclear
cell
cell
viabil
surfac
antigen
examin
trypan
blue
analysi
autophagi
character
light
microscopi
transmiss
electron
microscopi
morpholog
western
blot
microtubul
associ
light
chain
protein
lipid
acridin
orang
stain
acid
compon
vacuol
solubl
factor
contain
cultur
medium
serum
measur
elisa
result
found
sorafenib
inhibit
viabil
macrophag
accompani
morpholog
chang
characterist
autophagi
autophagyinduc
effect
valid
lipid
autophagosom
accumul
surfac
antigen
express
function
activ
macrophag
inhibit
sorafenib
includ
express
costimulatori
molecul
phagocytosi
product
reactiv
oxygen
speci
secret
reduc
sorafenib
conclus
sorafenib
addit
cancer
target
therapeut
agent
induc
autophagi
modul
function
human
macrophag
recruit
bone
marrow
peripher
blood
monocyt
enter
tissu
differenti
macrophag
major
cell
lineag
innat
immun
system
phagocytosi
remov
infect
microorgan
cellular
debri
macrophag
process
present
antigen
initi
specif
immun
respons
sorafenib
multikinas
inhibitor
capabl
block
raf
mekerk
pathway
vascular
endotheli
growth
factor
receptor
vegfr
plateletderiv
growth
factor
receptor
pdgfr
ckit
fmslike
tyrosin
kinas
flt
drug
approv
treatment
advanc
renal
cell
carcinoma
hepatocellular
carcinoma
other
anticanc
activ
sorafenib
report
capabl
modul
immunobiolog
activ
dendrit
cell
murin
regulatori
macrophag
popul
secret
rel
high
level
antiinflammatori
interleukin
il
autophagi
known
type
ii
program
cell
death
distinct
cellular
event
autophagi
character
format
autophagosom
degrad
intracellular
organel
materi
within
autophagosom
fuse
lysosom
process
occur
basal
level
respons
stress
serum
starvat
radiat
pharmacolog
agent
pathophysiolog
signific
autophagi
develop
macrophag
remain
controversi
role
autophagi
cell
surviv
remain
inconclus
exampl
cell
undergo
starvat
stress
may
process
autophagi
prosurviv
event
cancer
treatment
chemotherapeut
radiat
therapi
may
caus
antisurviv
manner
autophagi
present
studi
investig
effect
sorafenib
primari
cultur
human
macrophag
reveal
autophagi
intern
immunopharmacolog
j
u
r
n
l
h
e
p
g
e
w
w
w
e
l
e
v
e
r
c
l
c
e
n
p
induc
activ
sorafenib
macrophag
accompani
alter
macrophag
function
also
examin
macrophag
gener
human
peripher
blood
monocyt
briefli
peripher
blood
mononuclear
cell
obtain
healthi
donor
histopaqu
densiti
gradient
centrifug
amersham
buckinghamshir
uk
studi
approv
institut
ethic
committe
erythrocyt
lyse
treatment
ammonium
chlorid
subsequ
cell
purifi
highgradi
magnet
sort
use
minimac
system
microbead
puriti
isol
monocyt
accord
flow
cytometr
analysi
macrophag
gener
monocyt
cultur
rpmi
medium
supplement
fetalcalf
serum
everi
day
day
humidifi
co
incub
variou
concentr
sorafenib
bayer
leverkusen
germani
dissolv
dimethyl
sulfoxid
dmso
ad
begin
cell
cultur
evalu
effect
macrophag
experi
macrophag
activ
ad
lp
h
experi
equal
amount
dmso
ad
vehicl
control
trypan
blue
could
uptaken
viabl
macrophag
intact
cell
membran
assess
cell
membran
integr
cell
count
day
treatment
variou
concentr
sorafenib
use
trypan
blue
gibco
dye
exclus
method
anoth
set
experi
cell
count
day
treatment
sorafenib
cell
collect
use
trypsin
sigma
solut
wash
pb
equal
volum
cell
suspens
trypan
blue
solut
mix
count
number
viabl
cell
flow
cytometr
analysi
acridin
orang
stain
reactiv
oxygen
speci
product
dualcolor
immunolabel
perform
use
fluorescein
isothiocyan
fitc
phycoerythrin
pe
conjug
monoclon
antibodi
mab
mous
antihuman
mab
fitc
appropri
isotyp
control
purchas
serotec
oxford
uk
use
iggfitc
macrophag
incub
satur
concentr
primari
mab
follow
iggfitc
min
wash
twice
pb
cell
appli
fac
calib
flow
cytomet
bd
bioscienc
san
jose
ca
data
collect
analyz
use
cellquest
softwar
bd
bioscienc
acridin
orang
stain
macrophag
stain
acridin
orang
ngml
min
subject
flow
cytometri
test
reactiv
oxygen
speci
product
cell
collect
day
cultur
treat
lipopolysaccharid
lp
h
incub
min
pb
contain
dcfhda
thereaft
cell
wash
pb
two
time
subject
flow
cytometri
cell
centrifug
onto
microscop
slide
cytospin
centrifug
shandon
inc
pittsburgh
pa
stain
wrightgiemsa
solut
observ
light
microscopi
olympu
tokyo
japan
photograph
taken
digit
camera
shown
magnif
macrophag
harvest
trypsin
wash
fix
cold
glutaraldehyd
cacodyl
buffer
min
rins
pb
cell
postfix
osmium
tetroxid
embed
epon
resin
energi
beam
scienc
agawam
massachusett
semithin
section
cut
stain
toluidin
blue
examin
light
microscop
olympu
tokyo
japan
ultrathin
section
stain
uranyl
acet
fig
effect
sorafenib
macrophag
viabil
treatment
sorafenib
monocytederiv
human
macrophag
harvest
day
number
viabl
cell
count
use
trypan
blue
test
right
panel
cell
treat
mm
sorafenib
harvest
day
test
data
three
separ
experi
express
mean
sem
p
b
vs
dmso
control
group
reynold
lead
citrat
observ
transmiss
electron
microscop
jeol
co
tokyo
japan
whole
cell
lysat
isol
macrophag
treatment
variou
concentr
sorafenib
protein
concentr
determin
bicinchonin
acid
bca
assay
kit
pierc
rockford
illinoi
equal
amount
protein
lane
electrophores
sdspolyacrylamid
gel
protein
transfer
onto
nylon
blot
membran
membran
block
defat
milk
immunoblot
primari
antibodi
microtubul
associ
light
chain
protein
cell
signal
technolog
danver
room
temperatur
h
follow
incub
horseradish
peroxidaselabel
second
antibodi
transduct
laboratori
develop
use
enhanc
chemiluminesc
system
amersham
pharmacia
piscataway
new
jersey
conjug
form
call
distinguish
unconjug
form
faster
mobil
sd
gel
level
culturedmacrophag
supernat
measur
use
enzymelink
immunosorb
assay
elisa
r
system
accord
manufactur
instruct
phagocyt
activ
measur
accord
method
previous
publish
briefli
yeast
heatinactiv
diminish
infect
avoid
confus
phagocytosi
yeast
suspens
prepar
pb
densiti
ml
stock
macrophag
collect
day
cultur
treat
lipopolysaccharid
lp
h
wash
resuspend
ml
fcscontain
medium
incub
yeast
suspens
ml
min
cell
place
glass
slide
observ
invert
microscop
eclips
nikon
tokyo
japan
total
number
phagocytot
yeast
count
cell
result
express
mean
standard
error
mean
sem
comparison
experi
perform
use
unpair
student
ttest
p
valu
less
consid
statist
signific
viabil
macrophag
mildli
increas
treatment
low
intermedi
dose
sorafenib
comparison
control
group
howev
higher
concentr
sorafenib
significantli
inhibit
cell
viabil
macrophag
left
panel
fig
anoth
set
experi
sorafenib
ad
show
sorafenib
significantli
inhibit
viabil
macrophag
time
cours
right
panel
fig
morpholog
sorafenibtr
macrophag
exhibit
extens
develop
cytoplasm
vacuol
fig
morpholog
chang
rais
concern
autophagi
might
exist
sorafenibtr
macrophag
cytoplasm
vacuol
examin
transmit
electron
microscopi
doublemembran
structur
contain
organel
compon
characterist
autophagosom
identifi
sorafenibtr
macrophag
wherea
empti
singlelay
vacuol
note
control
group
fig
use
acridin
orang
stain
format
acid
vesicular
organel
avo
macrophag
demonstr
fig
microtubuleassoci
protein
light
chain
correspond
mammalian
homologu
yeast
autophagi
protein
aggreg
autophagosom
membran
autophagi
occur
western
blot
show
increas
convers
free
cytosol
phosphatidylethanolamineconjug
dosedepend
manner
fig
increas
lipid
persist
least
day
taken
togeth
suggest
sorafenib
could
induc
autophagi
human
macrophag
next
investig
whether
sorafenib
affect
classic
activ
macrophag
sorafenib
downregul
express
surfac
costimulatori
molecul
dosedepend
manner
fig
function
activ
macrophag
inhibit
sorafenib
term
phagocytosi
fig
product
reactiv
oxygen
speci
fig
level
secret
reduc
sorafenib
treatment
howev
level
demonstr
signific
chang
fig
sorafenib
oral
smallmolecul
target
therapeut
cancer
induc
autophagi
human
macrophag
accompani
cell
death
suppress
function
role
autophagi
macrophag
character
develop
autophagi
could
recogn
restrict
viral
bacteri
parasit
infect
insid
macrophag
contrast
virus
capabl
subvert
autophagi
surviv
sever
acut
respiratori
syndrom
coronaviru
thu
role
function
autophagi
macrophag
remain
controversi
need
clarifi
impli
pharmacolog
manipul
macrophag
induc
autophagi
might
potenti
benefit
diseas
outcom
clinic
immunolog
disord
howev
phenomenon
autophagi
induct
candid
agent
induc
autophagi
macrophag
report
preliminari
studi
sorafenib
could
induc
autophagi
macrophag
dendrit
cell
data
shown
indic
potenti
role
modul
innat
immun
furthermor
sorafenibinduc
autophagi
human
macrophag
could
categor
autophagyassoci
cell
death
polar
macrophag
classic
activ
altern
activ
pathway
differ
function
phenotyp
classic
activ
macrophag
endotoxin
lp
appli
standard
activ
demonstr
sorafenib
induc
autophagi
macrophag
steadi
state
function
classic
activ
macrophag
also
declin
whether
effect
extend
altern
activ
macrophag
remain
determin
particularli
macrophag
deviat
phenotyp
altern
activ
within
tumor
microenviron
may
variou
respons
sorafenib
treatment
given
sorafenib
current
recommend
target
therapeut
agent
cancer
safeti
advers
effect
elucid
result
suggest
find
autophagyinduc
activ
macrophag
could
extend
two
clinic
aspect
use
firstli
safeti
consider
immunotox
sorafenib
cancer
treatment
could
examin
secondli
immunosuppress
effect
sorafenib
macrophag
may
shed
light
treat
diseas
unwant
immun
respons
autoimmun
disord
reject
organ
transplant
conclus
sorafenib
induc
autophagi
modul
function
human
macrophag
possibl
role
unmet
immunomodulatori
effect
need
elucid
fig
lipid
macrophag
immunoblot
macrophag
treat
sorafenib
day
serum
starvat
subject
immunoblot
analysi
use
antibodi
antigapdh
antibodi
